Share Price, page-9527

In my view the future of Neuren depends on whether the board wants it to continue as a standalone entity or not. If they are angling for an exit strategy then they will keep everything simplified. ie no licensing deals to external pharma companies for 2591. Instead they will pursue non dilutive capital to fund the phase 3's. This makes Neu a more enticing takeover target with less to negotiate. I think something we have to consider in this instance will be a merger with Acadia who cant afford to buy us outright but could do a cash and script deal. They both operate in the same space and there will be obvious savings and synergy....

if the board want to keep their jobs and Neuren continues alone then the more complicated the deals to fund phase 3's the better!!